Clinical Trial Results:
A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs. 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to diabetes mellitus
Summary
|
|
EudraCT number |
2010-019795-74 |
Trial protocol |
BE CZ PT GB FR ES HU IT IE GR PL |
Global completion date |
17 Apr 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Apr 2016
|
First version publication date |
21 Apr 2016
|
Other versions |
|
Summary report(s) |
CRFB002D2304_CT_gov_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.